just want to touch on this bit mentioned in the bioshares article & know it's been talked of a bit lately. While i no doubt see the benefits of co-development & the signifcant up-side they present i guess my thoughts though - are we really in the right position yet ?
The whole reason the company turned to the current business model was to mitigate risk & financial burden at present we're (hopefully) well on the way to postive cash flow & even though the presentation lists 2013 for cash sustainability i fully expect this quarter to have a positive cash slant with the known payments so far.
Question is though can we afford to take on co-development without coming back to the market for cash ? ? Of course at present & for the current operations cash position is good but even co-development of a single candidate would likely drain everything we now have in the bank ? ?
Who knows - just rambling, but i would feel alot more comfortable treading water until a signifcant sum of capital through revenue is behind the company than trying to climb the castle when we are only teetering on achieving cash sustainability.
"Phylogica has reached the stage where it will intends to strike more co-development deals to gain more upside. These types of deals are structured according to an input/profit matrix, where the partners elect which part of the development they will fund and which corresponds to proportional commercial product rights."
PYC Price at posting:
4.1¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)